Specialist drug discovery and development firm, ImmuPharma (LON: IMM) said they are set to commence an international Phase 3 trial of Lupuzor in patients with systemic lupus erythematosus, in the second half of 2021.
ImmuPharma shares are currently trading 15.81% lower at the time of writing, priced at 9.95p per share.
Avion Pharmaceuticals, ImmuPharma’s licensing partner for Lupuzor and the company leading the drug development, met with the US food and Drug Administration (FDA) for a Type ‘A’ meeting on December 4th 2020.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
After the meeting, Avion and ImmuPharma plan to develop and validate a bioanalytical assay to confirm the clinical pharmacology and pharmacokinetic characterisations of Lupuzor before the commencement of Phase 3 trials.
A final guidance meeting between Avion and the FDA is planned for Q2, where Avion will submit the method for assessing the pharmacokinetics, as part of the trial.
ImmuPharma previously announced it initiated production of a new batch of Lupuzor clinical trial material specifically for the Phase 3 trial and has confirmed that it will be ready for the start of the study.
The FDA has informed Avion that a special protocol assessment won’t be applicable, and the conditional approval of Lupuzor has not been confirmed at this time.
“We are extremely pleased to see the positive progress of Lupuzor™ towards the commencement of the international Phase 3 trial with Avion. We will continue to work closely with Avion over the next period to ensure the start of the Phase 3 study remains on schedule for H2 2021,” said Dimitri Dimitrou, CEO of ImmuPharma.
